Berberine attenuates ischemia–reperfusion injury through inhibiting HMGB1 release and NF-κB nuclear translocation

Article metrics

  • 795 Accesses

  • 5 Citations


Inflammatory damage plays an important role in cerebral ischemic pathogenesis and represents a new target for treatment of stroke. Berberine is a natural medicine with multiple beneficial biological activities. In this study, we explored the mechanisms underlying the neuroprotective action of berberine in mice subjected transient middle cerebral artery occlusion (tMCAO). Male mice were administered berberine (25, 50 mg/kg/d, intragastric; i.g.), glycyrrhizin (50 mg/kg/d, intraperitoneal), or berberine (50 mg/kg/d, i.g.) plus glycyrrhizin (50 mg/kg/d, intraperitoneal) for 14 consecutive days before tMCAO. The neurological deficit scores were evaluated at 24 h after tMCAO, and then the mice were killed to obtain the brain samples. We showed that pretreatment with berberine dose-dependently decreased the infarct size, neurological deficits, hispathological changes, brain edema, and inflammatory mediators in serum and ischemic cortical tissue. We revealed that pretreatment with berberine significantly enhanced uptake of 18F-fluorodeoxyglucose of ischemic hemisphere comparing with the vehicle group at 24 h after stroke. Furthermore, pretreatment with berberine dose-dependently suppressed the nuclear-to cytosolic translocation of high-mobility group box1 (HMGB1) protein, the cytosolic-to nuclear translocation of nuclear factor kappa B (NF-κB) and decreased the expression of TLR4 in ischemic cortical tissue. Moreover, co-administration of glycyrrhizin and berberine exerted more potent suppression on the HMGB1/TLR4/NF-κB pathway than berberine or glycyrrhizin administered alone. These results demonstrate that berberine protects the brain from ischemia–reperfusion injury and the mechanism may rely on its anti-inflammatory effects mediated by suppressing the activation of HMGB1/TLR4/NF-κB signaling.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7


  1. 1.

    Faralli A, Bigoni M, Mauro A, Rossi F, Carulli D. Noninvasive strategies to promote functional recovery after stroke. Neural Plast. 2013;2013:854597.

  2. 2.

    Perez-de-Puig I, Miro-Mur F, Ferrer-Ferrer M, Gelpi E, Pedragosa J, Justicia C. Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol. 2015;129:239–57.

  3. 3.

    Ma F, Martinez-San Segundo P, Barcelo V, Morancho A, Gabriel-Salazar M, Giralt D, et al. Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice. Neurobiol Dis. 2016;91:236–46.

  4. 4.

    Pundik S, Xu K, Sundararajan S. Reperfusion brain injury focus on cellular bioenergetics. Neurology. 2012;79:S44–S51.

  5. 5.

    Kang R, Che RC, Zhang QH, Hou W, Wu S, Cao LZ, et al. HMGB1 in health and disease. Mol Asp Med. 2015;40:1–116.

  6. 6.

    Tsukagawa T, Katsumata R, Fujita M, Yasui K, Akhon C, et al. Elevated serum high-mobility group box-1 protein levels is associated with poor functional outcome in ischemic stroke. J Stroke Cerebrovasc Dis. 2017;26:2404–11.

  7. 7.

    Yang H, Wang HC, Ju ZL, Ragab AA, Lundback P, Long W, et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015;212:5–14.

  8. 8.

    Roy A, Srivastava M, Saqib U, Liu DF, Sugathan S, Bishnoi S, et al. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways. Int Immunopharmacol. 2016;40:79–89.

  9. 9.

    Zhao H, Chen Z, Xie LJ, Liu GF. Suppression of TLR4/ NF-κB signaling pathway improves cerebral ischemia-reperfusion injury in rats. Mol Neurobiol. 2017;4:1–9.

  10. 10.

    Van Delft MA, Huitema LF, Tas SW. The contribution of NF-kappaB signalling to immune regulation and tolerance. Eur J Clin Invest. 2015;45:529–39.

  11. 11.

    Hu J, Liu B, Zhao Q, Jin P, Hua F, Zhang Z, et al. Bone marrow stromal cells inhibits HMGB1-mediated inflammation after stroke in type 2 diabetic rats. Neuroscience. 2016;324:11–9.

  12. 12.

    Wang J, He GZ, Wang YK, Zhu QK, Chen W, Guo T. TLR4-HMGB1-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury. World J Gastroenterol. 2015;21:8314–25.

  13. 13.

    LiuT. Y, Zhang TT, Yu HM, Shen HL, Xia WL. Adjudin protects against cerebral ischemia reperfusion injury by inhibition of neuroinflammation and blood-brain barrier disruption. J Neuroinflamm. 2014;11:107.

  14. 14.

    Burrows F, Haley MJ, Scott E, Coutts G, Lawrence CB, Allan SM, et al. Systemic inflammation affects reperfusion following transient cerebral ischaemia. Exp Neurol. 2016;277:252–60.

  15. 15.

    Zhang ZJ, Li XH, Li FY, An LJ. Berberine alleviates postperative cognitive dysfunction by suppressing neuroinflammation in aged mice. Int Immunopharmacol. 2016;38:426–33.

  16. 16.

    Kulkami SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010;24:317–24.

  17. 17.

    Simoes Pires EN, Frozza RL, Hoppe JB, Melo Menezes B, Salbego CG. Berberine was neuroprotective against an in vitro model of brain ischemia: survival and apoptosis pathways involved. Brain Res. 2014;1557:26–33.

  18. 18.

    Long EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occusion without craniectomy in rats. Stroke. 1989;20:84–91.

  19. 19.

    Joo SP, Xie W, Xiong X, Xu B, Zhao H. Ischemic postcondition protects against focal cerebral ischemia by inhibiting brain inflammation while attenuating peripheral lymphopenia in mice. Neuroscience. 2013;243:149.

  20. 20.

    Mdzinarishvili A, Kiewert C, Kumar V, Hillert M, Klein J. Bilobalide prevents ischemia-induced edama formation in vitro and in vivo. Neuroscience. 2007;144:217–22.

  21. 21.

    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)Method. Methods. 2001;25:402–8.

  22. 22.

    Mirrone MM, Schiffer WK, Siddiq M, Dewey S, Tsirka S. PET imaging of glucose metabolism in a mouse model of temperol lobe epilepsy. Synapse. 2010;59:119–21.

  23. 23.

    Samson Y, Lapergue B, Hosseini H. Inflammation and ischaemic stroke: current status and future perspectives. Rev Neurol. 2005;161:1177–82.

  24. 24.

    Zhu Y, Guan YM, Huang HL, Wang QS. Human umbilical cord blood mesenchymal stem cell transplantation suppresses in flammatory responses and neuronal apoptosis during early stage of focal cerebral ischemia in rabbits. Acta Pharmacol Sin. 2014;35:585–91.

  25. 25.

    Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–62.

  26. 26.

    Huang JM, Hu J, Chen N, Hu ML. Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke. J Crit Care. 2013;28:792–7.

  27. 27.

    Ojo OO, Ryu MH, Jha A, Unruh H, Halayko AJ. High-mobility group box 1 promotes extracellular matrix synthesis and wound repair in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1354–66.

  28. 28.

    Su X, Wang J, Zhao J, Pan H, Mao L. Beneficial effects of ethyl pyruvate through inhibiting high-mobility group box 1 expression and TLR4/NF-κB pathway after traumatic brain injury in the rat. Mediat Inflamm 2011;2011:807142.

  29. 29.

    Crews FT, Qin L, Sheedy D, Vetrono RP, Zou J. High mobility groupbox1 /Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence. Biol Psychiatry. 2013;73:602–12.

  30. 30.

    Shi X, Li MD, Huang KB, Zhou SM, Hu YF, Pan SY, et al. HMGB1 binding heptamer peptide improves survival and ameliorates brain injury in rats after cardiac arrest and cardiopulmonary resuscitation. Neuroscience. 2017;360:128–38.

  31. 31.

    Jung HS, Joo JD, Kim DW, Roh M, Jeong JT, Noh SJ, et al. Effect of milrinone on the inflammatory response and NF-κB activation in renal ischemia-reperfusion injury in mice. Korean J Anesthesiol. 2014;66:136–42.

  32. 32.

    Jiang W, Fu F, Tian J, Zhu H, Hou J. Curculigoside A attenuates experimental cerebral ischemia injury in vitro and vivo. Neuroscience. 2011;192:572–9.

  33. 33.

    Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Rev Neurol. 2016;12:594–604.

  34. 34.

    Klimiec E, Kowalska K, Pasinka P, Pera J, Slowik A, Dziedzic T. Reduced release of TNF-α and IP-10 after ex vivo blood stimulation with endotoxin is associated with poor outcome after stroke. Cytokine. 2017;102:51–4.

  35. 35.

    Chacko AM, Watanabe S, Kalimuddin S, Tham JY, Ong J, Reolo M. 18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment response. JCI Insight. 2017;93474:1–12.

  36. 36.

    Montesino Orellana MR, Bentourkia M, Sarrhini O, Fulop T, Paquet N, Lavallee E, et al. Assessment of inflammation in large arteries with 18F-FDG in elderly. Comput Med Imaging Graph. 2013;37:459–65.

  37. 37.

    Ying KF, Chia JC, Chen KY, Wu KH, Chang KW, Jan ML, et al. Imaging of regional metabolic activity by 18F-FDG/PET in rats with transient cerebral ischemia. Appl Radiat Isot. 2009;67:1743–7.

  38. 38.

    Zhang XL, Zhang XJ, Wang CH, Li YH, Dong LP, Cui LL, et al. Neuroprotection of early and short-time applying berberine in the acute phase of cerebral ischemia: up-regulated pAkt, pGSK and pCREB, down-regulated NF-κB expression, ameliorated BBB permeability. Brain Res. 2012;1459:61–70.

Download references


This work was supported by the National Nature Science Foundation of China (No. 81773987).

Author information

Ying-dong Zhang, Chang-qing Yang, and Jian-guo Sun conceived and designed the study. Hai-dan Lu, Yan-li Zhao and Chao Guo performed the experiments. Hong-dong Zhao, Jun-shan Zhou, Feng Wang, and Yun-man Li analyzed the data. Jun-rong Zhu and Wei-rong Fang wrote the paper. Ying-dong Zhang, Chang-qing Yang, and Jian-guo Sun reviewed and edited the manuscript. All authors read and approved the manuscript.

Correspondence to Ying-dong Zhang or Chang-qing Yang or Jian-guo Sun.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

These are co-first authors: Jun-rong Zhu, Hai-dan Lu, Chao Guo

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • berberine
  • glycyrrhizin
  • ischemic stroke
  • inflammation
  • HMGB1
  • TLR4
  • NF-κB

Further reading